Biosafety hawks were initially optimistic that the incoming second Trump administration would at last place binding constraints on so-called "dangerous gain-of-function" research, in which pathogens are manipulated in laboratories to be more virulent or transmissible in humans.
The administration's picks for top health policy jobs—most notably National Institutes of Health (NIH) Director Jay Bhattacharya and Health and Human Services Secretary Robert F. Kennedy Jr.—are both gain-of-function critics who have asserted that this type of research created SARS-COV-2 in Wuhan, China.
In May, the White House issued an executive order creating a broader definition for dangerous gain-of-function research and promising that new restrictions on it would be issued within a few months.
